核苷（酸）类似物对慢性乙型肝炎患者干扰素-λ3诱导降低乙

StephenW

核苷（酸）类似物对慢性乙型肝炎患者干扰素-λ3诱导降低乙型肝炎表面抗原的影响
Machiko Umemura 1 , Koji Ogawa 1 , Kenichi Morikawa 1 , Akinori Kubo 1 , Yoshimasa Tokuchi 1 , Ren Yamada 1 , Takashi Kitagataya 1 , Taku Shigesawa 1 , Tomoe Shimazaki 1 , Megumi Kimura 1 , Kazuharu Suzuki 1 , Akihisa Nakamura 1 , Masatsugu Ohara 1、川岸直树 1、泉孝明 1、中井雅人 1、庄拓哉 1、须田刚辉 1、夏坂光辉 1、小野幸太 2、村田和本 3、杉山雅也 4、沟上正史 4、坂本直也 1
隶属关系
隶属关系

    1
    日本札幌北海道大学医学院和医学研究生院胃肠病学和肝病学系。
    2
    日本札幌北海道大学医院临床研究和医学创新中心。
    3
    日本下辅市自治医科大学感染与免疫学系病毒学系。
    4
    国家全球健康与医学中心肝炎与免疫学研究中心，日本市川。

    PMID: 35352445 DOI: 10.1111/hepr.13768

抽象的

背景和目的：核苷（酸）类似物（NAs）对乙型肝炎表面抗原（HBsAg）减少和干扰素-λ3（IFN-λ3）诱导的益处尚不清楚。本研究旨在探讨 NAs 对慢性乙型肝炎患者 HBsAg 降低的影响以及与血清 IFN-λ3 水平的关系。

方法：共有 91 名临床明显慢性乙型肝炎（慢性肝炎，57；肝肝硬化，34）参加了这项研究。在开始治疗前和治疗后 1、3 和 5 年测量接受 ETV 和 ADV/TDF 的患者的血清 IFN-λ3 水平。

结果：ETV 和 ADV/TDF 组血清 HBsAg 水平从基线到第 5 年的变化（平均值 ± 标准差）分别为 -0.38±0.46 和 -0.84±0.64 log10 IU/mL（P = 0.0004）。治疗期间ADV/TDF组血清IFN-λ3水平高于ETV组（P < 0.001）。血清 IFN-λ3 水平与第 48 周时 ADV/TDF 组的 HBsAg 降低呈负相关（r = -0.386，P = 0.038）。核苷酸类似物（ADV/TDF）治疗与 1 年时 -0.3 log HBsAg 下降相关的因素，多变量分析显示，NAs 治疗后 3 年 HBsAg 下降 -0.5 log，5 年 HBsAg 下降 -0.8 log。

结论：与核苷类似物 (ETV) 相比，核苷酸类似物 (ADV/TDF) 治疗在 IFN-λ3 诱导的同时降低了 HBsAg 水平。本文受版权保护。版权所有。

关键词：HBsAg；干扰素-λ3；阿德福韦酯；恩替卡韦水合物；富马酸替诺福韦酯。

本文受版权保护。版权所有。

StephenW

Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients
Machiko Umemura  1 , Koji Ogawa  1 , Kenichi Morikawa  1 , Akinori Kubo  1 , Yoshimasa Tokuchi  1 , Ren Yamada  1 , Takashi Kitagataya  1 , Taku Shigesawa  1 , Tomoe Shimazaki  1 , Megumi Kimura  1 , Kazuharu Suzuki  1 , Akihisa Nakamura  1 , Masatsugu Ohara  1 , Naoki Kawagishi  1 , Takaaki Izumi  1 , Masato Nakai  1 , Takuya Sho  1 , Goki Suda  1 , Mitsuteru Natsuizaka  1 , Kota Ono  2 , Kazumoto Murata  3 , Masaya Sugiyama  4 , Masashi Mizokami  4 , Naoya Sakamoto  1
Affiliations
Affiliations

    1
    Department of Gastroenterology and Hepatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan.
    2
    Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.
    3
    Division of Virology, Department of Infection and Immunity, Jichi Medical University, Shimotsuke, Japan.
    4
    The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan.

    PMID: 35352445 DOI: 10.1111/hepr.13768

Abstract

Background & aims: Benefits of nucleos(t)ide analogs (NAs) on hepatitis B surface antigen (HBsAg) reduction and interferon-lambda3 (IFN-λ3) induction are still not known. This study aimed to investigate the effects of NAs on HBsAg reduction and association with serum IFN-λ3 levels in chronic hepatitis B patients.

Methods: A total of 91 patients [51 treated with nucleoside analog entecavir hydrate (ETV) and 40 treated with nucleotide analog adefovir dipivoxil (ADF) or tenofovir disoproxil fumarate (TDF)] with clinically evident chronic hepatitis B (chronic hepatitis, 57; liver cirrhosis, 34) were enrolled in this study. Serum IFN-λ3 levels among patients receiving ETV and ADV/TDF were measured before the initiation of therapy and 1, 3, and 5 years post-therapy.

Results: The change (mean ± standard deviation) in serum HBsAg levels from baseline to year 5 was -0.38±0.46 and -0.84±0.64 log10 IU/mL in ETV and ADV/TDF groups, respectively (P = 0.0004). Higher serum IFN-λ3 levels were observed in ADV/TDF group compared with ETV group during treatment (P < 0.001). Serum IFN-λ3 levels showed negative correlation with HBsAg reduction in ADV/TDF group (r = -0.386, P = 0.038) at week 48. Nucleotide analogs (ADV/TDF) treatment has associated factors with -0.3 log HBsAg decline at 1 year, -0.5 log HBsAg decline at 3 year, and -0.8 log HBsAg decline at 5 year after NAs treatment on multivariate analysis.

Conclusions: Nucleotide analog (ADV/TDF) treatment reduced HBsAg levels greater compared with nucleoside analog (ETV) in parallel with IFN-λ3 induction. This article is protected by copyright. All rights reserved.

Keywords: HBsAg; IFN-λ3; adefovir dipivoxil; entecavir hydrate; tenofovir disoproxil fumarate.

This article is protected by copyright. All rights reserved.